[Comment] Trial and error in clinical studies: lessons from ATAMS

19:55 EST 5 Mar 2014 | The Lancet

Multiple sclerosis is one of the most prevalent neurological diseases in young adults and causes progressive and permanent disability in about a third of patients. Thus a treatment that halts or, even better, reverses disease progression is desperate...

Original Article: [Comment] Trial and error in clinical studies: lessons from ATAMS

NEXT ARTICLE

More From BioPortfolio on "[Comment] Trial and error in clinical studies: lessons from ATAMS"

Search BioPortfolio:
Loading
Advertisement
Advertisement

Searches Linking to this Story